64 related articles for article (PubMed ID: 27843173)
1. Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer.
Zhao Q; Xu WT; Shalieer T
Dis Markers; 2016; 2016():2325987. PubMed ID: 27843173
[No Abstract] [Full Text] [Related]
2. The potential mechanism of HIF-1α and CD147 in the development of triple-negative breast cancer.
Chen M; Liu Z; Zheng K; Hu C; Peng P
Medicine (Baltimore); 2024 Jun; 103(23):e38434. PubMed ID: 38847725
[TBL] [Abstract][Full Text] [Related]
3. Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets.
Xiao J; Huang F; Li L; Zhang L; Xie L; Liu B
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15003-15011. PubMed ID: 37610673
[TBL] [Abstract][Full Text] [Related]
4. Lactylproteome analysis indicates histone H4K12 lactylation as a novel biomarker in triple-negative breast cancer.
Cui Z; Li Y; Lin Y; Zheng C; Luo L; Hu D; Chen Y; Xiao Z; Sun Y
Front Endocrinol (Lausanne); 2024; 15():1328679. PubMed ID: 38779451
[TBL] [Abstract][Full Text] [Related]
5. Expression and Clinical Significance of MAGE-A Proteins and mRNA in Lung Cancer Patients: A Retrospective Study.
Zhu W; Xie HQ; Xie YQ; Lv XD
Altern Ther Health Med; 2024 Feb; 30(2):131-135. PubMed ID: 37856809
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of KLHL22 correlates with poor prognosis in patients with triple-negative breast cancer.
Zhang T; Liu J; Wang J; Zhang C
Transl Cancer Res; 2024 Feb; 13(2):798-807. PubMed ID: 38482450
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer.
Jiang W; Wang X; Zhang C; Xue L; Yang L
Oncol Lett; 2020 Mar; 19(3):1842-1848. PubMed ID: 32194678
[TBL] [Abstract][Full Text] [Related]
8. SEPT3 as a Potential Molecular Target of Triple-Negative Breast Cancer.
Yang LH; Wang GZ; Gao C
Int J Gen Med; 2024; 17():1605-1613. PubMed ID: 38686040
[TBL] [Abstract][Full Text] [Related]
9. Assessment of TUFT1 and Rac1-GTP levels in triple-negative breast cancer patients: clinical and pathological correlations.
Shi SF; Cai RX; Ren YF; Li Y; Li S; Yin TL; Jia DX; Li YJ
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38478261
[TBL] [Abstract][Full Text] [Related]
10. Retraction Note: MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer.
Qiu J; Yang B
Mol Cell Biochem; 2023 Dec; 478(12):2919. PubMed ID: 37498497
[No Abstract] [Full Text] [Related]
11. Proteomic Analysis Revealed the Potential Role of MAGE-D2 in the Therapeutic Targeting of Triple-Negative Breast Cancer.
Shi X; Liu C; Zheng W; Cao X; Li W; Zhang D; Zhu J; Zhang X; Chen Y
Mol Cell Proteomics; 2024 Jan; 23(1):100703. PubMed ID: 38128647
[TBL] [Abstract][Full Text] [Related]
12. Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report.
de Joode K; Veenbergen S; Kransse C; Kortleve D; Debets R; Mathijssen RHJ; Joosse A; Schreurs MWJ; Van der Veldt AAM
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36750254
[TBL] [Abstract][Full Text] [Related]
13. Cancer-Testis Antigens in Triple-Negative Breast Cancer: Role and Potential Utility in Clinical Practice.
Lam RA; Tien TZ; Joseph CR; Lim JX; Thike AA; Iqbal J; Tan PH; Yeong JPS
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359776
[TBL] [Abstract][Full Text] [Related]
14. Increased Melanoma-Associated Antigen C2 Expression Affords Resistance to Apoptotic Deathin Suspension-Cultured Tumor Cells.
Park D; Han S; Joo H; Ka HI; Soh S; Park J; Yang Y
J Breast Cancer; 2021 Apr; 24(2):138-152. PubMed ID: 33818016
[TBL] [Abstract][Full Text] [Related]
15. In Search of TGCT Biomarkers: A Comprehensive
Raos D; Krasic J; Masic S; Abramovic I; Coric M; Kruslin B; Katusic Bojanac A; Bulic-Jakus F; Jezek D; Ulamec M; Sincic N
Dis Markers; 2020; 2020():8841880. PubMed ID: 33224314
[TBL] [Abstract][Full Text] [Related]
16. MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer.
Qiu J; Yang B
Mol Cell Biochem; 2021 Jan; 476(1):1-10. PubMed ID: 32935296
[TBL] [Abstract][Full Text] [Related]
17. Emerging roles of the MAGE protein family in stress response pathways.
Florke Gee RR; Chen H; Lee AK; Daly CA; Wilander BA; Fon Tacer K; Potts PR
J Biol Chem; 2020 Nov; 295(47):16121-16155. PubMed ID: 32921631
[TBL] [Abstract][Full Text] [Related]
18. MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition.
Gu X; Mao Y; Shi C; Ye W; Hou N; Xu L; Chen Y; Zhao W
Onco Targets Ther; 2019; 12():7843-7855. PubMed ID: 31576142
[TBL] [Abstract][Full Text] [Related]
19. Study on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2.
Jiang S; Liu X; Li D; Yan M; Ju C; Sun J; Jiang F
Technol Cancer Res Treat; 2018 Jan; 17():1533033818797587. PubMed ID: 30198403
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
